Abstract
As innovative science dovetailed with a strong demand for both early- and later-stage drug candidates this year, venture capital funding for biotech firms surged. Overall venture capital investment in the biotech sector is set to “blow through the 2014 numbers,” says Greg Vlahos, life sciences partner at PricewaterhouseCoopers. Vlahos notes that venture capital investment in the biotech industry totaled $6.3 billion in 2014, the largest fund-raising year in history. By the end of the third quarter of 2015, biotech companies had already raked in $5.8 billion, with $2.1 billion of that coming in the third quarter alone. One driver for the uptick in activity is the good prospects investors have for recouping their cash. Merger and acquisition activity in the life sciences sector “has been running hot,” Vlahos notes. At the same time, young companies are having an easier time listing on public exchanges. “There’s a definite path to liquidity,” ...
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
